Lilly Grants $110K to GPPC to Study Regulatory Barriers to PGx Products

The drug firm that recently hired a PGx consultancy to improve its drug-approval rate has chosen a vocal critic of the FDA’s regulatory handling of genetic tests to identify barriers to bringing pharmacogenomic products to market, and to propose reforms.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.